Company news
Axsome Therapeutics, Inc. news in 2022
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 A...
December 6, 2022
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 27, 2022
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 8, 2022
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 6, 2022
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
October 26, 2022
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
October 20, 2022
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 19, 2022
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 9, 2022
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 2, 2022
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 28, 2022
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
September 20, 2022
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
September 13, 2022
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
September 7, 2022
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 6, 2022
Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor
August 31, 2022
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
August 18, 2022
Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
June 27, 2022
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
June 21, 2022
Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting
June 5, 2022
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
June 1, 2022
Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting
May 31, 2022
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
May 30, 2022
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
May 17, 2022
Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month
May 15, 2022
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
May 8, 2022
Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 1, 2022
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
May 1, 2022
Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022
April 24, 2022
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 27, 2022
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
March 10, 2022
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 1, 2022
Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 28, 2022
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 14, 2022
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
Calls in 2022
- Axsome Therapeutics (NASDAQ:AXSM) Q3 2022 Earnings Call
Nov 7, 2022
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q2 2022 Earnings Call
Aug 9, 2022
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q1 2022 Earnings Call
May 2, 2022
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q4 2021 Earnings Call
Mar 1, 2022
Transcript
Decks in 2022
- Corporate Update (June 2022)
Corporate update · 76 slides · Jun 28, 2022
- Merger or Acquisition (March 2022)
Merger or acquisition · 12 slides · Mar 28, 2022